Page last updated: 2024-08-22

tranylcypromine and ER-Negative PR-Negative HER2-Negative Breast Cancer

tranylcypromine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Calabretta, B; Cattelani, S; Chiodoni, C; Colombo, MP; Dominici, M; Fatatis, A; Ferrari-Amorotti, G; Grisendi, G; Manzotti, G; Rivasi, F; Shen, F; Soliera, AR1

Other Studies

1 other study(ies) available for tranylcypromine and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity.
    Neoplasia (New York, N.Y.), 2014, Volume: 16, Issue:12

    Topics: Animals; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Gene Silencing; Histone Demethylases; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Microscopy, Fluorescence; Monoamine Oxidase Inhibitors; Neoplasm Invasiveness; Neoplasm Metastasis; Plasmids; Real-Time Polymerase Chain Reaction; Snail Family Transcription Factors; Transcription Factors; Tranylcypromine; Triple Negative Breast Neoplasms

2014